Dr. Mark Steven Grimsley, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1611 Satellite Blvd Ste 3, Duluth, GA 30097 Phone: 770-614-6266 |
Dr. Priya Arcot-joshi, D.O Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3460 Summit Ridge Pkwy Ste 304, Duluth, GA 30096 Phone: 770-771-5115 Fax: 770-771-5116 |
Dr. Liem Chi Ngo, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4470 Satellite Blvd, Suite 204, Duluth, GA 30096 Phone: 770-858-5983 Fax: 770-858-5066 |
Young-tae Kim, Family Medicine Medicare: Medicare Enrolled Practice Location: 3610 Peachtree Industrial Blvd Ste 100, Duluth, GA 30096 Phone: 678-417-0332 |
Dr. Meena J Shah, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3490 Pleasant Hill Rd, Duluth, GA 30096 Phone: 770-814-2870 Fax: 770-814-2872 |
Scott Christopher Leeth, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3500 Mcclure Bridge Rd, Duluth, GA 30096 Phone: 770-476-3636 Fax: 770-476-5845 |
News Archive
BioBehavioral Diagnostics Company announced today that its poster was presented Friday, October 30, 2009 after it was accepted via a rigorous peer-review process and included as a New Research Poster presentation at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Honolulu, HI, October 27-November 1, 2009.
Professor Deljanin Ilic said: "In the setting of cardiovascular risk factors and cardiovascular disease the endothelium loses its normal function.1 Since endothelium derived nitric oxide is necessary to maintain an adequate vascular response, correction of endothelial dysfunction has become a goal of therapy."
Kaiser Health News / NPR "Last year, half of new doctors were hired by hospitals, according to the Medical Group Management Association, a professional organization for physician practices. According to a 2009 report by the American Medical Association, one in six doctors works for a hospital, and the number is quickly growing.
Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous administration of VELCADE (bortezomib) in patients with relapsed multiple myeloma. These data were presented at the 52nd annual meeting of the American Society of Hematology, held December 4-7 in Orlando, Florida.
› Verified 2 days ago